We are pleased that Dr Chris Hill, co-lead NICRN renal group, has recruited the first patient to the H-100-102 Hookipa study:

“A Randomised, Placebo-controlled Phase 2 study of HB-101, Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient 9R-) Patients Awaiting Kidney Transplantation from Living CMV – Seropositive Donors (D+)”

Read more about the study here